Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity

Pharmacological Research

Volumn 117, Issue , 2017, Pages 218-227

  Rezaee, Ramin ^a   Momtazi, Amir Abbas ^b   Monemi, Alireza ^a   Sahebkar, Amirhossein ^c,d  

^a NORTH KHORASAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chemotherapy; Cisplatin; Curcumin; Resistance; Toxicity

Indexed keywords

CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIPOXYGENASE; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CELL PROTECTION; CHEMOSENSITIZATION; DOWN REGULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE EXPRESSION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OTOPROTECTIVE ACTIVITY; OTOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CURCUMIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 85008173337     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.12.037     Document Type: Review

References (157)

1. [1] Sahin, K., Orhan, C., Tuzcu, M., Muqbil, I., Sahin, N., Gencoglu, H., Guler, O., Padhye, S.B., Sarkar, F.H., Mohammad, R.M., Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against Cisplatin-induced nephrotoxicity. Biol. Trace Elem. Res. 157:2 (2014), 156–163.
2. [2] Marur, S., Forastiere, A.A., Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin. Proc., 2008, 489–501 Elsevier).
3. [3] Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:47 (2003), 7265–7279.
4. [4] Worden, F.P., Kumar, B., Lee, J.S., Wolf, G.T., Cordell, K.G., Taylor, J.M., Urba, S.G., Eisbruch, A., Teknos, T.N., Chepeha, D.B., Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J. Clin. Oncol. 26:19 (2008), 3138–3146.
5. [5] Surendiran, A., Balamurugan, N., Gunaseelan, K., Akhtar, S., Reddy, K., Adithan, C., Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: an evaluative study. Indian J. Pharmacol., 42(1), 2010, 40.
6. [6] Hanigan, M.H., Devarajan, P., Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther., 1, 2003, 47.
7. [7] Amptoulach, S., Tsavaris, N., Neurotoxicity caused by the treatment with platinum analogues. Chemother. Res. Pract., 2011, 2011.
8. [8] Naqshbandi, A., Khan, W., Rizwan, S., Khan, F., Studies on the protective effect of flaxseed oil on cisplatin-induced hepatotoxicity. Hum. Exp. Toxicol. 31:4 (2012), 364–375.
9. [9] Ognjanović, B.I., Djordjević, N.Z., Matić, M.M., Obradović, J.M., Mladenović, J.M., Štajn, A.Š., Saičić, Z.S., Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int. J. Mol. Sci. 13:2 (2012), 1790–1803.
10. [10] B. Özyurt, M. Güleç, H. Özyurt, F. Ekici, Ö. Atis, A. Akbas. The effect of antioxidant caffeic acid phenethyl ester (CAPE) on some enzyme activities in cisplatin-induced neurotoxicity in rats, 2007.
11. [11] Burgeiro, A., Gajate, C., Dakir, E.H., Villa-Pulgarín, J.A., Oliveira, P.J., Mollinedo, F., Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells. Anticancer Drugs 22:6 (2011), 507–518.
12. [12] Brabec, V., Kasparkova, J., Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 8:3 (2005), 131–146.
13. [13] Kartalou, M., Essigmann, J.M., Mechanisms of resistance to cisplatin. Mutat. Res. 478:1 (2001), 23–43.
14. [14] Sedletska, Y., Giraud-Panis, M.-J., Malinge, J.-M., Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem.-Anti-Cancer Agents 5:3 (2005), 251–265.
15. [15] Ammon, H.P., Wahl, M.A., Pharmacology of curcuma longa. Planta Med. 57:1 (1991), 1–7.
16. [16] Panahi, Y., Ghanei, M., Bashiri, S., Hajihashemi, A., Sahebkar, A., Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res. 65:11 (2015), 567–573.
17. [17] Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 49:Pt 6 (2012), 580–588.
18. [18] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 28:5 (2014), 633–642.
19. [19] Panahi, Y., Alishiri, G.H., Parvin, S., Sahebkar, A., Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J. Dietary Suppl. 13:2 (2016), 209–220.
20. [20] Panahi, Y., Ghanei, M., Hajhashemi, A., Sahebkar, A., Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J. Dietary Suppl. 13:1 (2016), 93–105.
21. [21] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Majeed, M., Sahebkar, A., Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin. Nutr. 34:6 (2015), 1101–1108.
22. [22] Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., Akhlaghi, S., Ferns, G.A., Ghayour-Mobarhan, M., Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res. 27:12 (2013), 1883–1888.
23. [23] Panahi, Y., Saadat, A., Beiraghdar, F., Sahebkar, A., Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother. Res. 28:10 (2014), 1461–1467.
24. [24] Sahebkar, A., Serban, M.C., Ursoniu, S., Banach, M., Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J. Funct. Foods 18 (2015), 898–909.
25. [25] Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., Mirzaei, H.R., Salehi, H., Peyvandi, M., Pawelek, J.M., Sahebkar, A., Curcumin: a new candidate for melanoma therapy?. Int. J. Cancer 139:8 (2016), 1683–1695.
26. [26] Momtazi, A.A., Shahabipour, F., Khatibi, S., Johnston, T.P., Pirro, M., Sahebkar, A., Curcumin as a MicroRNA regulator in cancer: a review. Rev. Physiol. Biochem. Pharmacol. 171 (2016), 1–38.
27. [27] Iranshahi, M., Sahebkar, A., Hosseini, S.T., Takasaki, M., Konoshima, T., Tokuda, H., Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 17:3–4 (2010), 269–273.
28. [28] Iranshahi, M., Sahebkar, A., Takasaki, M., Konoshima, T., Tokuda, H., Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur. J. Cancer Prev. 18:5 (2009), 412–415.
29. [29] Teymouri, M., Pirro, M., Johnston, T.P., Sahebkar, A., Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular, molecular, and preclinical features. Biofactors, 2016, 10.1002/biof.1344 [Epub ahead of print].
30. [30] Panahi, Y., Rahimnia, A.R., Sharafi, M., Alishiri, G., Saburi, A., Sahebkar, A., Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother. Res. 28:11 (2014), 1625–1631.
31. [31] Momtazi, A.A., Derosa, G., Maffioli, P., Banach, M., Sahebkar, A., Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol. Diagn. Ther. 20:4 (2016), 335–345.
32. [32] Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., Akhlaghi, S., Ferns, G., Parizadeh, S.M., Ghayour-Mobarhan, M., Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal, 2014, 2014, 898361.
33. [33] Ghandadi, M., Sahebkar, A., Curcumin: an effective inhibitor of interleukin-6. Curr. Pharm. Des., 2016, 10.2174/1381612822666161006151605 [Epub ahead of print].
34. [34] Karimian, M.S., Pirro, M., Majeed, M., Sahebkar, A., Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev., 2016, 10.1016/j.cytogfr.2016.10.001 [Epub ahead of print].
35. [35] Sahebkar, A., Cicero, A.F., Simental-Mendia, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 107 (2016), 234–242.
36. [36] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Soflaei, S.S., Majeed, M., Sahebkar, A., Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition 32:10 (2016), 1116–1122.
37. [37] Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., Sahebkar, A., Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother. Res. 30:9 (2016), 1540–1548.
38. [38] Zabihi, N.A., Pirro, M., Johnston, T.P., Sahebkar, A., Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr. Pharm. Des., 2016, 10.2174/1381612822666161010115235 [Epub ahead of print].
39. [39] Sahebkar, A., Molecular mechanisms for curcumin benefits against ischemic injury. Fertil. Steril. 94:5 (2010), e75–e76 author rely e77.
40. [40] Shakeri, A., Sahebkar, A., Optimized curcumin formulations for the treatment of Alzheimer's disease: a patent evaluation. J. Neurosci. Res. 94:2 (2016), 111–113.
41. [41] Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S.M., Beiraghdar, F., Hoseininejad, S.L., Kolivand, M., Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 108:7 (2012), 1272–1279.
42. [42] Khonche, A., Biglarian, O., Panahi, Y., Valizadegan, G., Soflaei, S.S., Ghamarchehreh, M.E., Majeed, M., Sahebkar, A., Adjunctive therapy with curcumin for peptic ulcer: a randomized controlled trial. Drug Res. 66:8 (2016), 444–4448.
43. [43] Lelli, D., Sahebkar, A., Johnston, T.P., Pedone, C., Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacol. Res. 115 (2016), 133–148.
44. [44] Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., Ghayour-Mobarhan, M., An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin. J. Integr. Med. 21:5 (2015), 332–338.
45. [45] Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. 29:1 (2015), 17–21.
46. [46] Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., Ferns, G.A., Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother. Res. 27:3 (2013), 374–379.
47. [47] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement. Ther. Med. 22:5 (2014), 851–857.
48. [48] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with non-alcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68:3 (2016), 223–229.
49. [49] Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 39:2 (2013), 197–208.
50. [50] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11(2), 2014, 123.
51. [51] Sahebkar, A., A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin. Nutr. 33:3 (2014), 406–414.
52. [52] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68:3 (2016), 223–229.
53. [53] Sahebkar, A., Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat. Prod. Res. 29:6 (2015), 491–492.
54. [54] Somparn, P., Phisalaphong, C., Nakornchai, S., Unchern, S., Morales, N.P., Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. 30:1 (2007), 74–78.
55. [55] Barzegar, A., Moosavi-Movahedi, A.A., Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One, 6(10), 2011, e26012.
56. [56] Soobrattee, M.A., Neergheen, V.S., Luximon-Ramma, A., Aruoma, O.I., Bahorun, T., Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat. Res. 579:1 (2005), 200–213.
57. [57] Rao, M., Curcuminoids as potent inhibitors of lipid peroxidation. J. Pharm. Pharmacol. 46:12 (1994), 1013–1016.
58. [58] Basak, S.K., Zinabadi, A., Wu, A.W., Venkatesan, N., Duarte, V.M., Kang, J.J., Dalgard, C.L., Srivastava, M., Sarkar, F.H., Wang, M.B., Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells. Oncotarget, 6(21), 2015, 18504.
59. [59] Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:6 (2007), 807–818.
60. [60] Momtazi, A., Sahebkar, A., Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr. Pharm. Des. 22:28 (2016), 4386–4397.
61. [61] Kurzrock, R., Li, L., Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. ASCO Annual Meeting Proceedings, 2005 p. 4091.
62. [62] Zhang, L., Zhu, W., Yang, C., Guo, H., Yu, A., Ji, J., Gao, Y., Sun, M., Zhai, G., A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int. J. Nanomed. 7 (2012), 151–162.
63. [63] Yang, K.-Y., Lin, L.-C., Tseng, T.-Y., Wang, S.-C., Tsai, T.-H., Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC–MS/MS. J. Chromatogr. B 853:1 (2007), 183–189.
64. [64] Pan, M.-H., Huang, T.-M., Lin, J.-K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27:4 (1999), 486–494.
65. [65] Lao, C.D., Ruffin, M.T., Normolle, D., Heath, D.D., Murray, S.I., Bailey, J.M., Boggs, M.E., Crowell, J., Rock, C.L., Brenner, D.E., Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med., 6(1), 2006, 1.
66. [66] Liu, W., Zhai, Y., Heng, X., Che, F.Y., Chen, W., Sun, D., Zhai, G., Oral bioavailability of curcumin: problems and advancements. J. Drug Target., 2016, 1–9.
67. [67] Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Ming-Shiang, W., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:4B (2001), 2895–2900.
68. [68] Cuomo, J., Appendino, G., Dern, A.S., Schneider, E., McKinnon, T.P., Brown, M.J., Togni, S., Dixon, B.M., Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod. 74:4 (2011), 664–669.
69. [69] Liu, W., Zhai, Y., Heng, X., Che, F.Y., Chen, W., Sun, D., Zhai, G., Oral bioavailability of curcumin: problems and advancements. J. Drug Target. 24:8 (2016), 694–702.
70. [70] Dorai, T., Aggarwal, B.B., Role of chemopreventive agents in cancer therapy. Cancer Lett. 215:2 (2004), 129–140.
71. [71] Sinha, R., Anderson, D., McDonald, S., Greenwald, P., Cancer risk and diet in India. J. Postgrad. Med., 49(3), 2003, 222.
72. [72] Kelloff, G.J., Crowell, J.A., Steele, V.E., Lubet, R.A., Malone, W.A., Boone, C.W., Kopelovich, L., Hawk, E.T., Lieberman, R., Lawrence, J.A., Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 130:2 (2000), 467S–471S.
73. [73] Boone, C., Kelloff, G., Biomarker end-points in cancer chemoprevention trials. IARC Sci. Publ.(142), 1996, 273–280.
74. [74] Liu, J.-Y., Lin, S.-J., Lin, J.-K., Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14:5 (1993), 857–861.
75. [75] Kawamori, T., Lubet, R., Steele, V.E., Kelloff, G.J., Kaskey, R.B., Rao, C.V., Reddy, B.S., Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59:3 (1999), 597–601.
76. [76] Iranshahi, M., Sahebkar, A., Hosseini, S., Takasaki, M., Konoshima, T., Tokuda, H., Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 17:3 (2010), 269–273.
77. [77] Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., Aggarwal, B.B., Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:52 (2001), 7597–7609.
78. [78] Choudhuri, T., Pal, S., Agwarwal, M.L., Das, T., Sa, G., Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 512:1–3 (2002), 334–340.
79. [79] Chen, H., Zhang, Z., Zhang, Y., Zhou, D., Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 19:5A (1998), 3675–3680.
80. [80] Anto, R.J., Mukhopadhyay, A., Denning, K., Aggarwal, B.B., Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:1 (2002), 143–150.
81. [81] Shishodia, S., Amin, H.M., Lai, R., Aggarwal, B.B., Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70:5 (2005), 700–713.
82. [82] Rajasingh, J., Raikwar, H.P., Muthian, G., Johnson, C., Bright, J.J., Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK–STAT pathway in T cell leukemia. Biochem. Biophys. Res. Commun. 340:2 (2006), 359–368.
83. [83] Fang, J., Lu, J., Holmgren, A., Thioredoxin reductase is irreversibly modified by curcumin a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280:26 (2005), 25284–25290.
84. [84] Li, L., Aggarwal, B.B., Shishodia, S., Abbruzzese, J., Kurzrock, R., Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:10 (2004), 2351–2362.
85. [85] Roy, M., Mukherjee, S., Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac. J. Cancer Prev. 15:3 (2013), 1403–1410.
86. [86] Kuo, M.T., Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 11:1 (2009), 99–133.
87. [87] Singh, M., Singh, U., Mathur, N., Shukla, Y., Expression of P-glycoprotein is positively correlated with p53 in human papilloma virus induced squamous intraepithelial lesions of uterine cervix: poor prognosis association. Asian Pac. J. Cancer Prev. 13:12 (2012), 6039–6045.
88. [88] Dinkova-Kostova, A.T., Talalay, P., Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol. Nutr. Food Res. 52:S1 (2008), S128–S138.
89. [89] Ak, T., Gülçin, İ., Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact. 174:1 (2008), 27–37.
90. [90] Sreejayan, N., Rao, M., Free radical scavenging activity of curcuminoids. Arzneimittelforschung 46:2 (1996), 169–171.
91. [91] Das, K.C., Das, C.K., Curcumin (diferuloylmethane), a singlet oxygen (1O2) quencher. Biochem. Biophys. Res. Commun. 295:1 (2002), 62–66.
92. [92] Rao, M., Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol. 49:1 (1997), 105–107.
93. [93] Sumanont, Y., Murakami, Y., Tohda, M., Vajragupta, O., Matsumoto, K., Watanabe, H., Evaluation of the nitric oxide radical scavenging activity of manganese complexes of curcumin and its derivative. Biol. Pharm. Bull. 27:2 (2004), 170–173.
94. [94] Kim, J.E., Kim, A.R., Chung, H.Y., Han, S.Y., Kim, B.S., Choi, J.S., In vitro peroxynitrite scavenging activity of diarylheptanoids from Curcuma longa. Phytother. Res. 17:5 (2003), 481–484.
95. [95] Cohly, H.H., Taylor, A., Angel, M.F., Salahudeen, A.K., Effect of turmeric, turmerin and curcumin on H 2 O 2-induced renal epithelial (LLC-PK 1) cell injury. Free Radic. Biol. Med. 24:1 (1998), 49–54.
96. [96] Pan, Y., Wang, Y., Cai, L., Cai, Y., Hu, J., Yu, C., Li, J., Feng, Z., Yang, S., Li, X., Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br. J. Pharmacol. 166:3 (2012), 1169–1182.
97. [97] Yarru, L., Settivari, R., Gowda, N., Antoniou, E., Ledoux, D., Rottinghaus, G., Effects of turmeric (Curcuma longa) on the expression of hepatic genes associated with biotransformation, antioxidant, and immune systems in broiler chicks fed aflatoxin. Poult. Sci. 88:12 (2009), 2620–2627.
98. [98] Reyes-Fermín, L.M., González-Reyes, S., Tarco-Álvarez, N.G., Hernández-Nava, M., Orozco-Ibarra, M., Pedraza-Chaverri, J., Neuroprotective effect of α-mangostin and curcumin against iodoacetate-induced cell death. Nutr. Neurosci. 15:5 (2012), 34–41.
99. [99] Jeong, G.-S., Oh, G.-S., Pae, H.-O., Jeong, S.-O., Kim, Y.-C., Shin, M.-K., Seo, B.Y., Han, S.Y., Lee, H.S., Jeong, J.-G., Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression: ortho-methoxy groups are essential to enhance heme oxygenase activity and protection. Exp. Mol. Med. 38:4 (2006), 393–400.
100. [100] Lavoie, S., Chen, Y., Dalton, T.P., Gysin, R., Cuénod, M., Steullet, P., Do, K.Q., Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J. Neurochem. 108:6 (2009), 1410–1422.
101. [101] Ye, S., Hou, Z., Zhong, L., Zhang, Q., Effect of curcumin on the induction of glutathione S-transferases and NADP (H): quinone oxidoreductase and its possible mechanism of action. Yao Xue Xue Bao=Acta Pharm. Sin. 42:4 (2007), 376–380.
102. [102] Rushworth, S.A., Ogborne, R.M., Charalambos, C.A., O'Connell, M.A., Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem. Biophys. Res. Commun. 341:4 (2006), 1007–1016.
103. [103] Rojo, A.I., Medina-Campos, O.N., Rada, P., Zúñiga-Toalá, A., López-Gazcón, A., Espada, S., Pedraza-Chaverri, J., Cuadrado, A., Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3. Free Radic. Biol. Med. 52:2 (2012), 473–487.
104. [104] Cuadrado, A., Moreno-Murciano, P., Pedraza-Chaverri, J., The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin. Ther. Targets 13:3 (2009), 319–329.
105. [105] Eggler, A.L., Gay, K.A., Mesecar, A.D., Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol. Nutr. Food Res. 52:S1 (2008), S84–S94.
106. [106] Calabrese, V., Bates, T.E., Mancuso, C., Cornelius, C., Ventimiglia, B., Cambria, M.T., Di Renzo, L., De Lorenzo, A., Dinkova-Kostova, A.T., Curcumin and the cellular stress response in free radical-related diseases. Mol. Nutr. Food Res. 52:9 (2008), 1062–1073.
107. [107] Dinkova-Kostova, A.T., Fahey, J.W., Talalay, P., Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol. 382 (2004), 423–448.
108. [108] Trujillo, J., Chirino, Y.I., Molina-Jijón, E., Andérica-Romero, A.C., Tapia, E., Pedraza-Chaverrí, J., Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol. 1:1 (2013), 448–456.
109. [109] Goel, A., Kunnumakkara, A.B., Aggarwal, B.B., Curcumin as “Curecumin”: from kitchen to clinic. Biochem. Pharmacol. 75:4 (2008), 787–809.
110. [110] Abe, Y., Hashimoto, S., Horie, T., Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol. Res. 39:1 (1999), 41–47.
111. [111] Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S.S., Keum, Y.-S., Park, K.-K., Lee, S.S., Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res. 480 (2001), 243–268.
112. [112] Jobin, C., Bradham, C.A., Russo, M.P., Juma, B., Narula, A.S., Brenner, D.A., Sartor, R.B., Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J. Immunol. 163:6 (1999), 3474–3483.
113. [113] Julie, S., Jurenka, M., Anti-inflammatory properties of curcumin, a major constituent. Altern. Med. Rev., 14(2), 2009.
114. [114] Podratz, J.L., Knight, A.M., Ta, L.E., Staff, N.P., Gass, J.M., Genelin, K., Schlattau, A., Lathroum, L., Windebank, A.J., Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 41:3 (2011), 661–668.
115. [115] Al Moundhri, M.S., Al-Salam, S., Al Mahrouqee, A., Beegam, S., Ali, B.H., The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J. Med. Toxicol. 9:1 (2013), 25–33.
116. [116] Rybak, L.P., Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 15:5 (2007), 364–369.
117. [117] Al-Khatib, T., Cohen, N., Carret, A.-S., Daniel, S., Cisplatinum ototoxicity in children, long-term follow up. Int. J. Pediatr. Otorhinolaryngol. 74:8 (2010), 913–919.
118. [118] Kolinsky, D.C., Hayashi, S.S., Karzon, R., Mao, J., Hayashi, R.J., Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J. Pediatr. Hematol. Oncol. 32:2 (2010), 119–123.
119. [119] Salehi, P., Akinpelu, O.V., Waissbluth, S., Peleva, E., Meehan, B., Rak, J., Daniel, S.J., Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model. Otol. Neurotol. 35:7 (2014), 1131–1139.
120. [120] Sohn, S.-H., Lee, H., Nam, J.-y., Kim, S.-H., Jung, H.-J., Kim, Y., Shin, M., Hong, M., Bae, H., Screening of herbal medicines for the recovery of cisplatin-induced nephrotoxicity. Environ. Toxicol. Pharmacol. 28:2 (2009), 206–212.
121. [121] Ugur, S., Ulu, R., Dogukan, A., Gurel, A., Yigit, I.P., Gozel, N., Aygen, B., Ilhan, N., The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity. Ren. Fail. 37:2 (2015), 332–336.
122. [122] Pabla, N., Dong, Z., Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73:9 (2008), 994–1007.
123. [123] El-Beshbishy, H.A., Bahashwan, S.A., Aly, H.A., Fakher, H.A., Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur. J. Pharmacol. 668:1 (2011), 278–284.
124. [124] An, Y., Xin, H., Yan, W., Zhou, X., Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp. Toxicol. Pathol. 63:3 (2011), 215–219.
125. [125] Yousef, M., Saad, A., El-Shennawy, L., Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem. Toxicol. 47:6 (2009), 1176–1183.
126. [126] Soetikno, V., Sari, F.R., Lakshmanan, A.P., Arumugam, S., Harima, M., Suzuki, K., Kawachi, H., Watanabe, K., Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2–keap1 pathway. Mol. Nutr. Food Res. 57:9 (2013), 1649–1659.
127. [127] Aleksunes, L.M., Augustine, L.M., Scheffer, G.L., Cherrington, N.J., Manautou, J.E., Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 250:2 (2008), 82–88.
128. [128] Tirkey, N., Kaur, G., Vij, G., Chopra, K., Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol., 5(1), 2005, 15.
129. [129] Ramesh, G., Reeves, W.B., TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110:6 (2002), 835–842.
130. [130] Dong, Z., Atherton, S., Tumor necrosis factor-α in cisplatin nephrotoxicity: a homebred foe?. Kidney Int. 72:1 (2007), 5–7.
131. [131] Li, M., Balamuthusamy, S., Khan, A.M., Maderdrut, J.L., Simon, E.E., Batuman, V., Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure. J. Mol. Neurosci. 43:1 (2011), 58–66.
132. [132] Ramesh, G., Reeves, W.B., Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int. 65:2 (2004), 490–499.
133. [133] Ueki, M., Ueno, M., Morishita, J., Maekawa, N., Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. J. Biosci. Bioeng. 115:5 (2013), 547–551.
134. [134] Fetoni, A., Paciello, F., Mezzogori, D., Rolesi, R., Eramo, S., Paludetti, G., Troiani, D., Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br. J. Cancer 113:10 (2015), 1434–1444.
135. [135] Jaggi, A.S., Singh, N., Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291:1 (2012), 1–9.
136. [136] Brouwers, E.E., Huitema, A.D., Boogerd, W., Beijnen, J.H., Schellens, J.H., Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 48:6 (2009), 832–841.
137. [137] Siegal, T., Haim, N., Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66:6 (1990), 1117–1123.
138. [138] Cavaletti, G., Alberti, P., Frigeni, B., Piatti, M., Susani, E., Chemotherapy-induced neuropathy. Curr. Treat. Options Neurol. 13:2 (2011), 180–190.
139. [139] James, S.E., Dunham, M., Carrion-Jones, M., Murashov, A., Lu, Q., Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology 31:2 (2010), 188–194.
140. [140] Öztürk, G., Anlar, Ö., Erdoğan, E., Kösem, M., Özbek, H., Türker, A., The effect of Ginkgo extract EGb761 in cisplatin-induced peripheral neuropathy in mice. Toxicol. Appl. Pharmacol. 196:1 (2004), 169–175.
141. [141] Carozzi, V.A., Marmiroli, P., Cavaletti, G., The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr. Cancer Drug Targets 10:7 (2010), 670–682.
142. [142] McDonald, E.S., Randon, K.R., Knight, A., Windebank, A.J., Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis. 18:2 (2005), 305–313.
143. [143] Mendonca, L.M., da Silva Machado, C., Teixeira, C.C.C., de Freitas, L.A.P., Bianchi, M.d.L.P., Antunes, L.M.G., Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. Neurotoxicology 34 (2013), 205–211.
144. [144] Waseem, M., Parvez, S., Mitochondrial dysfunction mediated cisplatin induced toxicity: modulatory role of curcumin. Food Chem. Toxicol. 53 (2013), 334–342.
145. [145] Zhou, B., Huang, J., Zuo, Y., Li, B., Guo, Q., Cui, B., Shao, W., Du, J., Bu, X., 2a, a novel curcumin analog, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage. Eur. J. Pharmacol. 707:1 (2013), 130–139.
146. [146] Kumar, B., Yadav, A., Hideg, K., Kuppusamy, P., Teknos, T.N., Kumar, P., A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS One, 9(3), 2014, e93208.
147. [147] Zhang, H., Yu, T., Wen, L., Wang, H., Fei, D., Jin, C., Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment. Exp. Ther. Med. 6:5 (2013), 1317–1321.
148. [148] Weir, N.M., Selvendiran, K., Kutala, V.K., Tong, L., Vishwanath, S., Rajaram, M., Tridandapani, S., Anant, S., Kuppusamy, P., Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer. Biol. Ther. 6:2 (2007), 178–184.
149. [149] Chen, P., Li, J., Jiang, H.-G., Lan, T., Chen, Y.-C., Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway. Tumor Biol. 36:5 (2015), 3591–3599.
150. [150] Chanvorachote, P., Pongrakhananon, V., Wannachaiyasit, S., Luanpitpong, S., Rojanasakul, Y., Nimmannit, U., Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest. 27:6 (2009), 624–635.
151. [151] Chang, P.-Y., Peng, S.-F., Lee, C.-Y., Lu, C.-C., Tsai, S.-C., Shieh, T.-M., Wu, T.-S., Tu, M.-G., Chen, M.Y., Yang, J.-S., Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int. J. Oncol. 43:4 (2013), 1141–1150.
152. ®) to alleviate the adverse effects of cancer treatment. Phytother. Res. 28:3 (2014), 444–450.
153. [153] Palipoch, S., Punsawad, C., Chinnapun, D., Suwannalert, P., Amelioration of cisplatin-induced nephrotoxicity in rats by curcumin and α-tocopherol. Trop. J. Pharm. Res. 12:6 (2014), 973–979.
154. [154] Trujillo, J., Molina-Jijón, E., Medina-Campos, O.N., Rodríguez-Muñoz, R., Reyes, J.L., Loredo, M.L., Barrera-Oviedo, D., Pinzón, E., Rodríguez-Rangel, D.S., Pedraza-Chaverri, J., Curcumin prevents cisplatin-induced decrease in the tight and adherens junctions: relation to oxidative stress. Food Funct. 7:1 (2016), 279–293.
155. [155] Waseem, M., Kaushik, P., Parvez, S., Mitochondria-mediated mitigatory role of curcumin in cisplatin‐induced nephrotoxicity. Cell Biochem. Funct. 31:8 (2013), 678–684.
156. [156] Song, K.I., Park, J.Y., Lee, S., Lee, D., Jang, H.-J., Kim, S.-N., Ko, H., Kim, H.Y., Lee, J.W., Hwang, G.S., Protective effect of tetrahydrocurcumin against cisplatin-induced renal damage: in vitro and in vivo studies. Planta Med. 81:4 (2015), 286–291.
157. [157] Fetoni, A.R., Eramo, S.L., Paciello, F., Rolesi, R., Podda, M.V., Troiani, D., Paludetti, G., Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction. Otol. Neurotol. 35:5 (2014), e169–e177.